Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$1.92M$1.92M+22.3% vs Q3 2018 Net Income-$1.13M-$1.13MN/M vs Q3 2018 EPS Diluted-$0.02-$0.02N/M vs Q3 2018 Gross Profit$879,000+44.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,338,000N/M Free Cash Flowderived-$1,466,000N/M Margins · derivedGross margin45.7%+7.0 pt vs Q3 2018
Operating margin-60.4%+24.7 pt vs Q3 2018
Net margin-58.6%+26.1 pt vs Q3 2018
ended Mar 31, 2019 · filed May 10, 2019 · 40 d after period end